MiMedx Group, Inc. (MDXG)
NASDAQ: MDXG · IEX Real-Time Price · USD
7.31
+1.15 (18.67%)
At close: May 1, 2024, 4:00 PM
7.27
-0.04 (-0.55%)
After-hours: May 1, 2024, 7:32 PM EDT
MiMedx Group Revenue
MiMedx Group had revenue of $334.51M in the twelve months ending March 31, 2024, with 19.20% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $84.71M with 18.18% year-over-year growth. In the year 2023, MiMedx Group had annual revenue of $321.48M with 20.03% growth.
Revenue (ttm)
$334.51M
Revenue Growth
+19.20%
P/S Ratio
3.23
Revenue / Employee
$373,754
Employees
895
Market Cap
1.08B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 321.48M | 53.64M | 20.03% |
Dec 31, 2022 | 267.84M | 25.82M | 10.67% |
Dec 31, 2021 | 242.02M | -6.22M | -2.50% |
Dec 31, 2020 | 248.23M | -51.02M | -17.05% |
Dec 31, 2019 | 299.26M | -59.86M | -16.67% |
Dec 31, 2018 | 359.11M | 37.97M | 11.82% |
Dec 31, 2017 | 321.14M | 76.12M | 31.07% |
Dec 31, 2016 | 245.02M | 57.72M | 30.82% |
Dec 31, 2015 | 187.30M | 69.07M | 58.43% |
Dec 31, 2014 | 118.22M | 59.04M | 99.77% |
Dec 31, 2013 | 59.18M | 32.13M | 118.76% |
Dec 31, 2012 | 27.05M | 19.29M | 248.60% |
Dec 31, 2011 | 7.76M | 6.97M | 883.74% |
Dec 31, 2010 | 788.87K | - | - |
Mar 31, 2009 | 0 | - | - |
Mar 31, 2008 | 0 | - | - |
Dec 31, 2007 | 0 | - | - |
Dec 31, 2006 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BioCryst Pharmaceuticals | 331.41M |
Standard BioTools | 106.34M |
Simulations Plus | 64.67M |
MacroGenics | 58.75M |
EyePoint Pharmaceuticals | 46.02M |
Bicycle Therapeutics | 26.98M |
Liquidia | 17.49M |
Perspective Therapeutics | 1.43M |
MDXG News
- 1 day ago - MIMEDX Announces First Quarter 2024 Operating and Financial Results - GlobeNewsWire
- 15 days ago - MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30 - GlobeNewsWire
- 6 weeks ago - MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing - GlobeNewsWire
- 2 months ago - MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results - GlobeNewsWire
- 2 months ago - MIMEDX to Present at TD Cowen 44th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28 - GlobeNewsWire
- 3 months ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG - PRNewsWire
- 3 months ago - MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing - GlobeNewsWire